AVITA Medical Inc

AVH: XASX (AUS)
View Stock Summary
Morningstar Rating for Stocks Fair Value Economic Moat Capital Allocation
LOCK|&$><b$LOCK|DfLOCK|CfWL%c#

Avita Medical Earnings: Fair Value Estimate Cut on Unlikely Vitiligo Reimbursement Support

Avita Medical's first-quarter 2025 sales grew just 1% on fourth-quarter 2024 to USD 18 million. Avita is also suspending its vitiligo efforts given uncertainty of achieving reimbursement support and cutting costs to focus on acute wound care. Shares fell as much as 20% on the result.

Sponsor Center